Ausdauer-Leistungsfähigkeit von Triathlon-Athleten mit Typ-1-DiabetesS. Boehncke; K. Poettgen; C. Maser-gluth; J. Reusch; W. Boehncke; K. Badenhoop · 2009

Is psoriasis a T-cell disease?B. J. Nickoloff; J. M. Schröder; P. Von Den Driesch ; S. P. Raychaudhuri; E. M. Farber; W.-H. Boehncke; V. B. Morhenn; E. W. Rosenberg; M. P. Schön; M. F. Holick · 2000

German S3-guidelines on the treatment of psoriasis vulgaris (short version)A. Nast; W. H. Boehncke; U. Mrowietz; H. M. Ockenfels; S. Philipp; K. Reich; T. Rosenbach; A. Sammain; M. Schlaeger; M. Sebastian; W. Sterry; V. Streit; M. Augustin; R. Erdmann; J. Klaus; J. Koza; S. Müller; H. D. Orzechowski; S. Rosumeck; G. Schmid-Ott; T. Weberschock; B. Rzany · 2012

Biological therapies in the systemic management of psoriasis: International Consensus ConferenceW. Sterry; J. Barker; W.-H. Boehncke; J.D. Bos; S. Chimenti; E. Christophers; M. De La Brassinne; C. Ferrandiz; C. Griffiths; A. Katsambas; K. Kragballe; C. Lynde; A. Menter; J.-P. Ortonne; K. Papp; J. Prinz; B. Rzany; J. Ronnevig; J.-H. Saurat; M. Stahle; F.M. Stengel; P. Van De Kerkhof; J. Voorhees · 2004

Positive patch test reactions to celecoxib may be due to irritation and do not correlate with the results of oral provocationM. Kleinhans; L. Linzbach; S. Zedlitz; R. Kaufmann; W. -H. Boehncke · 2002

Antibodies to desmogleins 1 and 3, but not to BP180, induce blisters in human skin grafted onto SCID miceD. Zillikens; E. Schmidt; S. Reimer; I. Chimanovitch; K. Hardt-Weinelt; C. Rose; E. B. Bröcker; M. Kock; W. H. Boehncke · 2001

German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version)A. Nast; I. Kopp; M. Augustin; K. B. Banditt; W. H. Boehncke; M. Follmann; M. Friedrich; M. Huber; C. Kahl; J. Klaus; J. Koza; I. Kreiselmaier; J. Mohr; U. Mrowietz; H. M. Ockenfels; H. D. Orzechowski; J. Prinz; K. Reich; T. Rosenbach; S. Rosumeck; M. Schlaeger; G. Schmid-Ott; M. Sebastian; V. Streit; T. Weberschock; B. Rzany · 2007